Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 13.93 USD 2.65% Market Closed
Market Cap: 1.1B USD

Wall Street
Price Targets

VRDN Price Targets Summary
Viridian Therapeutics Inc

Wall Street analysts forecast VRDN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRDN is 41.57 USD with a low forecast of 22.22 USD and a high forecast of 64.05 USD.

Lowest
Price Target
22.22 USD
60% Upside
Average
Price Target
41.57 USD
198% Upside
Highest
Price Target
64.05 USD
360% Upside
Viridian Therapeutics Inc Competitors:
Price Targets
4587
PeptiDream Inc
105% Upside
MRUS
Merus NV
71% Upside
XGN
Exagen Inc
1% Upside
688382
InventisBio Co Ltd
14% Upside
SNDX
Syndax Pharmaceuticals Inc
258% Upside
ORKA
Oruka Therapeutics Inc
255% Upside
STTK
Shattuck Labs Inc
118% Upside
002675
Yantai Dongcheng Biochemicals Co Ltd
8% Upside

Revenue
Forecast

Revenue Estimate
Viridian Therapeutics Inc

For the last 8 years the compound annual growth rate for Viridian Therapeutics Inc's revenue is -26%. The projected CAGR for the next 3 years is 861%.

-26%
Past Growth
861%
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Viridian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Viridian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-70%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VRDN's stock price target?
Price Target
41.57 USD

According to Wall Street analysts, the average 1-year price target for VRDN is 41.57 USD with a low forecast of 22.22 USD and a high forecast of 64.05 USD.

What is Viridian Therapeutics Inc's Revenue forecast?
Projected CAGR
861%

For the last 8 years the compound annual growth rate for Viridian Therapeutics Inc's revenue is -26%. The projected CAGR for the next 3 years is 861%.

Back to Top